Acumen Pharmaceuticals
ABOS
60 hedge funds and large institutions have $158M invested in Acumen Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 9 closing their positions.
153% more call options, than puts
Call options by funds: $534K | Put options by funds: $211K
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
20% more funds holding
Funds holding: 50 → 60 (+10)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
2.94% more ownership
Funds ownership: 68.55% → 71.48% (+2.9%)
43% less capital invested
Capital invested by funds: $278M → $158M (-$120M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$3.72M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.61M |
| 3 |
Millennium Management
New York
|
+$1.31M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.16M |
| 5 |
Two Sigma Investments
New York
|
+$590K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$4.04M |
| 2 |
MCM
Moore Capital Management
New York
|
-$2.66M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.09M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.53M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.34M |
ABOS Hedge Fund Activity: Q4 2022 in Review
60 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2022, worth a combined $158M — down 43% from $278M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ABOS positions and 9 closed out — a net gain of 10 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Pathstone Family Office, adding an estimated $3.72M. The largest seller was Commodore Capital, cutting an estimated $4.04M.
- 60 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2022, up from 50 in Q3 2022.
- Funds reported $158M of Acumen Pharmaceuticals stock for Q4 2022, down 43% quarter-over-quarter.
- 19 funds opened new Acumen Pharmaceuticals positions in Q4 2022 and 9 closed out, a net change of +10 holders.
- The largest Acumen Pharmaceuticals buyer in Q4 2022 was Pathstone Family Office, an estimated $3.72M added.
- The largest Acumen Pharmaceuticals seller in Q4 2022 was Commodore Capital, an estimated $4.04M sold.
Based on aggregated 13F filings for Q4 2022.